Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Pittsburgh, Pennsylvania 15232


Purpose:

The purposes of this study are to examine the effects of a new combination of drugs, celecoxib (Celebrex®) and irinotecan (CPT-11), with standard radiation therapy on people before they undergo surgery; to determine what effects this combination has on pancreatic cancer; and to determine the highest dose of celecoxib and irinotecan that can be given safely without causing severe side effects. While not an endpoint, it is hoped that this combination will also shrink tumors enough for excision.


Study summary:

The purposes of this study are to examine the effects of a new combination of drugs, celecoxib (Celebrex®) and irinotecan (CPT-11), with standard radiation therapy on people before they undergo surgery; to determine what effects this combination has on pancreatic cancer; and to determine the highest dose of celecoxib and irinotecan that can be given safely without causing severe side effects. While not an endpoint, it is hoped that this combination will also shrink tumors enough for excision.


Criteria:

Inclusion Criteria: - Locally advanced carcinoma of the pancreas - Arterial invasion or encasement - Invasion/encasement of the portomesenteric veins - Patients who have been previously denied operation - Obstructive jaundice must be drained with a polyethylene biliary stent or surgical bypass prior to beginning treatment. - White blood cell count > 3500 per ml and platelet count > 100,000 per ml - Serum creatinine ≤ 1.5 mg/dl - Bilirubin ≤ 1.5 - ECOG performance status < 2 Exclusion Criteria: - Prior chemotherapy, radiotherapy, or investigational agents for pancreatic cancer - Evidence of distant metastasis or malignant lymphadenopathy - Concurrent malignancies - History of allergic reactions to celecoxib or to sulfa drugs - No non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, magnesium or aluminum containing antacids, fluconazole or lithium may be administered within 5 days of study entry, during the study and for the 30 days following the completion of all study treatments. - Pregnant women and lactating women - Uncontrolled or serious intercurrent illness - HIV-positive patients receiving combination antiretroviral therapy


NCT ID:

NCT00177853


Primary Contact:

Principal Investigator
A. J. Moser, MD
University of Pittsburgh Medical Center Department of Surgery, Division of Surgical Oncology


Backup Contact:

N/A


Location Contact:

Pittsburgh, Pennsylvania 15232
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.